Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-09-01 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2021-09-01 English
20-F
Annual Report FY 2021
2021-08-31 English
Preliminary Final Report including Appendix 4E 227 pages 2.9MB
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the United States SEC, which is an annual report for foreign private issuers. It covers the fiscal year ended June 30, 2021, and includes detailed sections such as financial data, operating and financial review, directors and management information, major shareholders, and financial statements. The length of the document (15,000 characters) and the detailed table of contents indicate it is a full annual report rather than a brief announcement or certification. Therefore, it fits the definition of an Annual Report (10-K equivalent for foreign issuers). FY 2021
2021-08-30 English
Annual Financial Results Presentation 34 pages 3.4MB
Annual Report Classification · 95% confidence The document is titled 'Operational Highlights & Financial Results for the Year Ended June 30, 2021' and contains detailed financial data, including revenue, expenses, and loss figures for the fiscal year ending June 30, 2021. It also discusses business operations, pipeline, manufacturing, and regulatory pathways. The presence of comprehensive financial statements and operational highlights for a full fiscal year indicates this is a full annual report. The document is about 15,000 characters long, which is consistent with a detailed report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2021
2021-08-30 English
MSB Annual Financial Results and Operational Progress 10 pages 649.9KB
Annual Report Classification · 95% confidence The document is a detailed report from Mesoblast Limited covering operational highlights and financial results for the fiscal year ended June 30, 2021. It includes extensive financial data, clinical trial results, regulatory updates, manufacturing investments, and intellectual property information. The presence of comprehensive financial results, operational highlights, and detailed clinical and regulatory information for a full fiscal year indicates this is a full annual report rather than a brief earnings release or a regulatory announcement. The document length (15,000 characters) and depth of content further support classification as an Annual Report (10-K equivalent). There is no indication that this is merely an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the appropriate classification is Annual Report (10-K). FY 2021
2021-08-30 English
Mesoblast 2021 Full Year Financial Results Webcast 1
Regulatory Filings Classification · 95% confidence The document is a corporate update announcing a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2021. It provides details about the webcast timing and access, company background, and contact information. The document does not contain actual financial statements or detailed financial analysis but rather serves as an announcement for an upcoming webcast where such information will be discussed. The document length is short (2803 characters) and it primarily serves as a notification rather than a full financial report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain substantive financial data or the report itself.
2021-08-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.